Compare BridgeBio Pharma Inc (BBIO) vs FedEx Corporation (FDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs FedEx Corporation — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while FedEx Corporation trades at $321.95 (market cap $75.37B). The key difference: FedEx Corporation is far larger — about 4.5× BridgeBio Pharma Inc's market cap, and FedEx Corporation pays a 1.53% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | FDX | |
|---|---|---|
Market Cap | $16.61B | $75.37B |
Sector | Health | Industrials |
52-Week High | $90.17 | $338.75 |
52-Week Low | $47.29 | $180.51 |
Enterprise Value | $18.16B | $105.00B |
Dividend Yield | — | 1.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
FedEx (FDX) trades at $318.57, up 0.85% with a bullish technical signal despite mixed moving averages. The company shows solid fundamentals with a P/E of 17.17 and net income margin of 4.68%, supported by recent earnings beats. Network transformation initiatives and premium revenue mix are driving operational improvements, while analyst consensus remains strongly positive with a $360.27 price target.
Outlook remains favorable with projected revenue growth to $94.7B in 2026 and continued margin expansion. Key risks include competitive pressures in logistics and macroeconomic sensitivity. The stock offers value with reasonable valuation metrics and strong institutional support, though investors should monitor execution of cost-saving initiatives and freight demand trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →
